Kwality Pharmaceuticals Ltd has announced that it has received registration approval for Bleomycin 15 IU in Mexico, enabling the company to begin sales and distribution in the region. Bleomycin is a widely prescribed oncology medicine, used in the treatment of Hodgkin’s lymphoma, testicular cancer, and certain squamous cell carcinomas.
The approval marks a significant milestone in Kwality Pharmaceuticals’ strategy to expand into highly regulated international markets. With this registration, the company is further reinforcing its global footprint in the oncology segment, offering patients access to advanced and affordable cancer treatments.
According to the company, the business potential in Mexico is projected to be around USD 1 million in the first year, with supplies scheduled to commence before the end of Q2 FY26.
Highlighting its commitment, Kwality Pharmaceuticals stated that it will continue to expand its oncology portfolio across international markets to make high-quality medicines more accessible worldwide.